11.11.2022 02:04:15
|
European Commission Approves Sanofi-GSK COVID Booster Vaccine
(RTTNews) - Sanofi (SNYNF, SNY) and GSK Plc.'s (GSK.L, GSK) next-generation COVID-19 vaccine, VidPrevtyn Beta, has been approved by the European Commission as a booster for the prevention of COVID-19 in adults 18 years of age and older.
Next-generation COVID-19 vaccines are based on a variant-adapted approach, using a strain other than the parental strain of SARS-CoV-2 (D614 strain). The vaccine is based on the Beta variant antigen and includes GSK's pandemic adjuvant.
The vaccine is indicated as a booster for active immunisation against SARS-CoV-2 in adults who have previously received a mRNA or adenoviral COVID-19 vaccine.
Shipments of the vaccine are ready to be distributed to European countries as per the Advance Purchase Agreements, the companies said.
For More Such Health News, visit rttnews.com

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu GlaxoSmithKline plc (GSK) (ADRS)mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu GlaxoSmithKline plc (GSK) (ADRS)mehr Analysen
Aktien in diesem Artikel
Sanofi S.A. (spons. ADRs) | 51,00 | 0,00% |
|
Sanofi S.A. | 104,18 | 0,89% |
|